Inclusion Criteria:

          1. abilities to understand and the willingness to provide written informed consent;

          2. patients are ≥ 18 and ≤ 70 years old;

          3. recurrent glioblastoma patients with measurable tumors. Patients have received
             standard care of medication, such as Gross Total Resection with concurrent
             Radio-chemotherapy (~54 - 60 Gy, TMZ). Patients must either not be receiving
             dexamethasone or receiving ≤ 4 mg/day at the time of leukopheresis;

          4. Malignant cells are EGFRvIII positive confirmed by IHC, quantitative PCR or
             sequencing;

          5. karnofsky performance score (KPS) ≥ 60;

          6. life expectancy >3 months;

          7. satisfactory bone marrow, liver and kidney functions as defined by the following:
             absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000
             /mm^3; Bilirubin < 1.5×ULN; alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) < 2.5×ULN; creatinine < 1.5×ULN;

          8. peripheral blood absolute lymphocyte count must be above 0.8×10^9/L;

          9. satisfactory heart functions;

         10. patients must be willing to follow the orders of doctors;

         11. women of reproductive potential (between 15 and 49 years old) must have a negative
             pregnancy test within 7 days of study start. Male and female patients of reproductive
             potential must agree to use birth control during the study and 3 months post study.

        Exclusion Criteria:

          1. a prior history of gliadel implantation 4 weeks before this study start or antibody
             based therapies;

          2. HIV positive;

          3. hepatitis B infection or hepatitis C infection;

          4. history of autoimmune disease, or other diseases require long-term administration of
             steroids or immunosuppressive therapies;

          5. history of allergic disease, or allergy to CAR T cells or study product excipients;

          6. patients already enrolled in other clinical study;

          7. patients, in the opinion of investigators, may not be eligible or not able to comply
             with the study.